Global Common Warts Opportunities 2025, Forecast To 2034
26 Mar, 2025
What Is The Current and Historic Market Size Analysis Of The Common Warts Market?
The common warts market has seen considerable growth due to a variety of factors.
• The market for common warts has seen robust growth in recent years. The market value is estimated to rise from $2.13 billion in 2024 to $2.26 billion in 2025, showing a compound annual growth rate (CAGR) of 6.2%.
The historical growth has been fueled by factors such as heightened awareness about skin health, an escalating occurrence of warts, a surge in preference for non-invasive treatments, growing adoption of cryotherapy, and an increase in dermatology clinics.
What Are The Predictions for The Common Warts Market?
The common warts market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, substantial comprehensive development is predicted for the common warts market, expected to reach a total worth of $2.83 billion by 2029, featuring a compound annual growth rate (CAGR) of 5.8%.
The anticipated growth in this period can be attributed to numerous causes, including an aging population, increased occurrence of viral infections, the surge in the application of advanced skin treatment methods, a rising demand for personalized therapy, and an enhanced preference by customers for home-based solutions. Key trends to expect in the prospective period comprise of innovations in skin treatment approaches, expansion in health care infrastructure, advancements in technology applied to wart removal treatments, greater understanding of available treatment alternatives, and a trend towards treatments that are less invasive.
What Main Forces Are Fueling Expansion In The Common Warts Market?
The escalation in the occurrence of viral infections is projected to fuel the expansion of the common warts market. Viral infections are illnesses that arise from the invasion, multiplication, and distribution of viruses within the body, impacting cells and immune responses. This escalation is induced by globalization, climate change, urbanization, deforestation, and weakened immune responses. The treatment of common warts is aimed at the human papillomavirus (HPV), which is accountable for wart formation, offering crucial relief to patients with viral infections by limiting viral spread, easing discomfort, and fostering healing, thereby avoiding complications such as further infections or scarring while enhancing the patient's living conditions. For example, based on data from the Centers for Disease Control and Prevention, a US government agency, in 2024, the rate of PCR-verified varicella cases increased by 62%, rising from 29% to 47% in the previous five years. Additionally, as per the National Foundation for Infectious Diseases, a US health organization, in January 2023, it's estimated that every year the United States has 14 million new cases of HPV infection. Consequently, the escalation in the occurrence of viral infections is motivating the growth in the common warts market.
What Are The Core Segments Of The Global Common Warts Market?
The common warts market covered in this report is segmented –
1) By Treatment Method: Cryotherapy, Laser Treatment, Electrosurgery, Topical Medications
2) By Patient Demographics: Children, Adults, Elderly
3) By Disease Stage: Initial Stage, Moderate Stage, Severe Stage
4) By End User: Hospitals, Dermatology Clinics, Home Care
Subsegments:
1) By Cryotherapy: Liquid Nitrogen Therapy, Carbon Dioxide Therapy
2) By Laser Treatment: Pulsed-Dye Laser Therapy, Carbon Dioxide (CO
2) Laser Therapy
3) By Electrosurgery: Curettage And Electrosurgical Removal, High-Frequency Electrosurgical Ablation
4) By Topical Medications: Salicylic Acid-Based Therapy, Immunotherapy-Based Topicals, Retinoid-Based Therapy
Which Emerging Trends Are Reshaping The Common Warts Market Size?
Leading firms in the common warts market are emphasizing on progressing innovative treatments such as dermatological therapies, aiming to fulfill the increasing need for effective and readily available solutions. This concentration is to boost patient outcomes and broaden their footprint in the dermatology sector. Dermatological therapies are treatments catered to skin conditions encompassing infections, inflammations, and disorders. For instance, in May 2024, American pharmaceutical company Verrica Pharmaceuticals entered into a licensing agreement with Torii Pharmaceutical Co. Ltd., a company based in Japan. The collaboration's goal is to financially support a global Phase 3 clinical trial for YCANTH, a treatment for common warts. This agreement aids in the developmental stages of YCANTH, thus increasing its potential influence globally. Torii Pharmaceuticals plans to inject financial aid into advancing the study. This partnership enhances both companies’ dermatology portfolios and their presence in international markets.
Who Are the Key Players In The Common Warts Market?
Major companies operating in the common warts market are:
• Major players in the market are AbbVie Inc.
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Limited
• Perrigo Company plc
• Holland & Barrett International Limited
• Prestige Consumer Healthcare Inc.
• Maruho Co. Ltd.
• Novan Inc.
• X4 Pharmaceuticals Inc.
• Aclaris Therapeutics Inc.
• Verrica Pharmaceuticals Inc.
• RXi Pharmaceuticals Corporation
• Scholl’s Wellness Company
• Nielsen BioSciences Inc.
• Cassiopea S.p.A.
• Orgenesis Inc.
• KinoPharma Inc.
• Naturasil
• Veradermics Inc.
• KinoPharma Co. Ltd.
What Are The Regional Insights Into The Common Warts Market?
North America was the largest region in the common warts market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the common warts market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.